Benefits
Immune activity markers in healthy adults
Taken by mouth, some postbiotics have shifted laboratory immune measures. In one controlled trial, a heat-killed Lactobacillus plantarum strain for 12 weeks raised lymphocyte proliferation to a test stimulus and the Th1-to-Th2 ratio versus control. These are blood markers, not fewer infections, the result belongs to that one strain, and the work was industry linked.
Upper respiratory symptom support in susceptible adults
In a 12-week trial of about 241 adults, a heat-killed Lactobacillus paracasei strain did not lower how many people caught a cold overall. In a prespecified subgroup who had caught a cold the year before, the lower dose was linked to fewer symptom days and lower symptom scores. The finding is for that strain only and the study was run by its maker.
Digestive comfort and stool regularity
In a placebo-controlled pilot of 80 adults with digestive discomfort and sluggish bowels, 500 mg a day of a baker's-yeast fermentate for 6 weeks improved stool consistency in the whole group and eased bloating and fullness in those with moderate symptoms. It was a small, maker-linked pilot of one fermentate, not a treatment for a bowel disorder.
Shifts in gut microbiome composition
In the same yeast-fermentate pilot, stool testing showed changes in gut bacteria, including a rise in groups reported to be low in constipated people and, in one subgroup, in Akkermansia muciniphila. Laboratory gut models point the same way. These are composition changes with one product, and a microbiome shift is not by itself a proven health outcome.
No live organisms to keep alive
Because the microbes are already inactivated, nothing has to survive manufacturing, storage or stomach acid, so these products are shelf stable and need no refrigeration, and they cannot multiply or seed the bloodstream. That reasoning is why they are often discussed for people with a weakened immune system, but the cited trials did not enrol that group, so it stays a rationale rather than a tested result.
Each postbiotic is a different preparation
A yeast fermentate, a heat-killed Lactobacillus, an inactivated Bacillus, a pasteurized Akkermansia and a fermented-soy product are different organisms made different ways. Evidence for one says nothing about another, which is why the branded forms are kept on separate pages and why the label strain is what matters when you compare products.
Mechanism of action
Microbial fragments engage immune receptors
Inactivation leaves cell-wall parts such as peptidoglycans, teichoic acids and surface proteins intact. In laboratory work these are recognized by pattern-recognition receptors (for example Toll-like receptors) on immune cells in the gut lining, which can switch on signaling without a live infection. This is a proposed route built from cell studies.
Metabolites from fermentation
Some postbiotics are fermentation products that carry small molecules such as short-chain fatty acids, polyphenols, peptides or deglycosylated isoflavones. These compounds are proposed to influence the gut environment and inflammatory signaling, mostly shown in laboratory or animal models rather than measured as outcomes in people.
Acts without colonizing the gut
Unlike a live probiotic, a postbiotic contains no organisms that can grow or take up residence. Any effect has to come from contact between the inactivated material and the gut lining and its immune tissue, which is why these products are taken regularly rather than to establish a colony.
Clinical trials
Randomized, double-blind, placebo-controlled pilot of a baker's-yeast fermentate (EpiCor) at 500 mg a day for 6 weeks; funded by the ingredient maker (Pinheiro et al. 2017, BMC Complement Altern Med).
80 adults with gastrointestinal discomfort and constipation.
Stool consistency improved in the whole group after 2 weeks (P = 0.023), and bloating and feeling of fullness improved in the moderate-symptom subgroup; a rise in stool frequency was only near significant (P = 0.083 to 0.090). Stool testing showed microbiome changes, including more Akkermansia muciniphila in the moderate subgroup. A small, maker-linked pilot of one product.
Randomized, double-blind, placebo-controlled trial of heat-killed Lactobacillus plantarum L-137, 10 mg a day for 12 weeks, in healthy adults; authors included the developer's staff (Hirose et al. 2006, J Nutr).
60 healthy adults (30 men, 30 women), mean age about 56 years.
Compared with control, lymphocyte proliferation to a test stimulus and the Th1-to-Th2 ratio rose (P = 0.036 and P = 0.002), and a quality-of-life score was higher at week 8. Natural killer activity and other innate markers were measured but did not differ. Blood markers only, not rates of illness, and specific to strain L-137.
Randomized, double-blind, placebo-controlled trial of heat-killed Lactobacillus paracasei MCC1849 (LAC-Shield) at 10 or 30 billion cells a day for 12 weeks; run by the maker (Murata et al. 2018, Benef Microbes).
241 healthy young adults.
Overall there was no difference between groups in how many people caught a cold. In a prespecified subgroup who had caught a cold the previous year, the 10 billion-cell dose was linked to lower cold incidence, fewer symptom days and lower symptom scores. A single maker-run trial of one strain, with the main result confined to a subgroup.
Randomized, double-blind, placebo-controlled proof-of-concept trial of Akkermansia muciniphila, live or pasteurized, at about 10 billion cells a day for 3 months in overweight, insulin-resistant adults (Depommier et al. 2019, Nat Med).
40 overweight or obese insulin-resistant adults enrolled; 32 completed.
Only the pasteurized (non-living, postbiotic) form beat placebo: it improved insulin sensitivity (+28.6%, P = 0.002), lowered insulin and total cholesterol, and slightly reduced body weight (not significant). Both forms were safe over 3 months. This is the pasteurized bacterium, a different organism from the others here.
Randomized, double-blind, placebo-controlled trial of heat-killed Lactobacillus LB (Lacteol) with oral rehydration in children with mild acute diarrhea (Salazar-Lindo et al. 2007, J Pediatr Gastroenterol Nutr).
80 non-dehydrated children aged 3 months to 4 years with acute watery diarrhea.
Median duration of diarrhea was 10.0 hours with the heat-killed preparation versus 16.6 hours with placebo, a difference that was not significant overall (P = 0.275). In children already ill more than 24 hours, duration from that point was shorter (P = 0.044). Pediatric acute-illness research under medical care, not everyday adult use.
Randomized, double-blind, placebo-controlled trial of a fermented-soy postbiotic (Gastro-AD), up to three 1 g sachets per episode as needed for 3 weeks; funded by the maker (Fatani et al. 2020, BMC Res Notes).
50 adults with mild to moderate heartburn.
The primary outcomes were not met: heartburn severity and frequency, a gastrointestinal symptom scale and a reflux quality-of-life score did not differ from placebo. A few individual quality-of-life items favored fermented soy, and heartburn frequency was lower during a 1-week washout. A small, maker-funded trial of one product.
Randomized, double-blind, placebo-controlled trial of heat-killed Lactobacillus paracasei KW3110 (EyeMuse) for 8 weeks in adults with screen-related eye fatigue; funded by the maker (Morita et al. 2018, Nutrients).
62 healthy Japanese adults aged 35 to 45 with screen-related eye fatigue.
A marker of eye fatigue (critical flicker frequency) only tended to hold up better with the strain overall; the difference reached significance at week 4 in a subgroup with high baseline fatigue (P = 0.020). Included here to show a postbiotic studied for a completely different outcome, with results specific to that strain.